Previous Article | Next Article ![]()
Infection and Immunity, June 2000, p. 3491-3501, Vol. 68, No. 6
Program in Molecular and Cellular Biology, University of
Massachusetts, Amherst,1 and Department
of Biological Sciences, Clark Science Center, Smith College,
Northampton,2 Massachusetts; Lindsley F. Kimball Research Institute, New York Blood Center, New York, New
York3; and Institute of Cell, Animal,
and Population Biology, University of Edinburgh, Edinburgh EH9 3JT,
United Kingdom4
Received 30 November 1999/Returned for modification 11 January
2000/Accepted 17 March 2000
The search for appropriate vaccine candidates and drug targets
against onchocerciasis has so far been confronted with several limitations due to the unavailability of biological material, appropriate molecular resources, and knowledge of the parasite biology.
To identify targets for vaccine or chemotherapy development we have
undertaken two approaches. First, cDNA expression libraries were
constructed from life cycle stages that are critical for establishment
of Onchocerca volvulus infection, the third-stage larvae
(L3) and the molting L3. A gene discovery effort was then initiated by
random expressed sequence tag analysis of 5,506 cDNA clones. Cluster
analyses showed that many of the transcripts were up-regulated and/or
stage specific in either one or both of the cDNA libraries when
compared to the microfilariae, L2, and both adult stages of the
parasite. Homology searches against the GenBank database facilitated
the identification of several genes of interest, such as proteinases,
proteinase inhibitors, antioxidant or detoxification enzymes, and
neurotransmitter receptors, as well as structural and housekeeping
genes. Other O. volvulus genes showed homology only to
predicted genes from the free-living nematode Caenorhabditis elegans or were entirely novel. Some of the novel proteins
contain potential secretory leaders. Secondly, by immunoscreening the molting L3 cDNA library with a pool of human sera from putatively immune individuals, we identified six novel immunogenic proteins that
otherwise would not have been identified as potential vaccinogens using
the gene discovery effort. This study lays a solid foundation for a
better understanding of the biology of O. volvulus as well as for the identification of novel targets for filaricidal agents and/or vaccines against onchocerciasis based on immunological and
rational hypothesis-driven research.
Onchocerciasis, or river blindness,
is the second leading cause of infectious blindness in humans.
According to the World Health Organization, an estimated 18 million
people are infected with the parasite, with over 1 million at risk of
visual impairment (79). Ivermectin was shown to be both safe
and effective in the treatment of onchocerciasis and has become the
drug of choice for mass distribution (79). However,
ivermectin is only effective against microfilariae released into the
skin, and prolonged annual ivermectin therapy of up to 10 to 15 years
is required for clearance of onchocerciasis from a human population
(63). The potential development of drug-resistant strains of
the parasite also demands the identification of alternative drug
candidates for onchocerciasis control (67). The number of
suitable targets for chemotherapy that have been identified in filarial
and other parasitic nematodes is low, due in part to an inadequate
understanding of the basic biology of these parasites. Ivermectin, as
well as the other commonly used drugs, does not exploit known targets
in the filarial parasites and was discovered by chance. Previous
research has centered on important metabolic processes such as energy
metabolism and nucleotide synthesis (75). However,
nonmetabolic processes are also important either for parasite survival
within the host or for propagation. Filarial nematodes do not multiply
in the definitive host but molt, grow, and mature for a period
following infection, after which they devote their energy almost
entirely to microfilaria production. None of the proteins involved in
these processes have yet been explored as possible drug targets.
An additional tool in the control of onchocerciasis would be the
development of a prophylactic vaccine. One essential step in the
development of immunoprophylaxis is the identification and
immunochemical characterization of potential vaccine candidates that
play a role in stimulating protective host immunity. There is mounting
evidence that naturally acquired immunity against Onchocerca
volvulus infection can occur in humans (20).
Additionally, work in animal models suggests that the protective immune
responses are directed at incoming infective third-stage larvae (L3)
(37, 45, 62, 72). Interestingly, studies from animal models
of filarial infections suggest that protective immune responses may inhibit the growth, development, and molting of the L3 to L4 (19, 37, 72). This suggests that molting L3 (mL3) proteins as well as
excretory-secretory (ES) products are an important source of protective
antigens (19, 46). Serum samples from O. volvulus putatively immune (PI) individuals and protected animals recognized similar antigens present only in day 2 extracts and ES products of
molting larvae (32).
Due to the paucity of parasite material, construction of
cDNA expression libraries and molecular cloning approaches are
important methods for isolating and characterizing protein
antigens. Immunoscreening of cDNA libraries, constructed from adult
worms (18) and more recently from L3
(SAW94WL-OvL3), using polyclonal antibodies has resulted in
the identification of more than 50 O. volvulus antigens (http://helios.bto.ed.ac.uk/mbx/fgn/OnchoNet/onchotable1.html). About 10 of the proteins are also present in larval stages of O. volvulus, some of which have been shown to confer partial
protection against L3 challenge in surrogate rodent models of
onchocercal infections (34, 39, 70, 71). However, there is
still a need for the identification of novel larval proteins,
particularly from the mL3 stage, that may prove to be better candidates
for protective immunity alone or in combination with other molecules.
In an attempt to identify, clone, and characterize novel drug targets
and vaccine candidates from the infective and molting larval stages of
O. volvulus, we developed a bipartite program. (i) An
expressed sequence tag (EST) project was undertaken to survey gene
expression in both L3 and mL3 stages of the parasite life cycle. The
thousands of new genes cloned in this effort and their expression
profiles have been used to identify a set of potentially interesting
vaccine and drug target candidates. (ii) The mL3 cDNA expression
library was screened using a pool of sera from O. volvulus
PI individuals. We describe the results of this effort, which has led
to the identification of potential targets for drug and vaccine
development and provided new information about genes that are highly
expressed at these critical stages of the parasite life cycle.
O. volvulus cDNA library construction.
All
parasite material was prepared in the Tropical Medicine Research
Station, Kumba, Cameroon. L3 were obtained from flies 7 days after
infection with skin microfilariae. To obtain molting larvae, freshly
dissected L3 were cultured in vitro in the presence of a 1:1 mixture of
Iscove's modified Dulbecco's medium and NCTC-135, 20% fetal calf
serum, and antibiotic-antimycotic solution (Life Technologies,
Gaithersburg, Md.) for 3 days at 37°C. Larvae were collected after 1, 2, or 3 days in culture, washed in Tris-EDTA buffer and then
snap-frozen in liquid nitrogen. Ultrastructural examination by electron
microscopy confirmed that these cultured larvae had started the molting
process, as the separation between the cuticle of L3 and the newly
synthesized cuticle of L4 was evident in some of the cross sections
(data not shown).
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Identification of Potential Vaccine and Drug Target Candidates
by Expressed Sequence Tag Analysis and Immunoscreening of
Onchocerca volvulus Larval cDNA Libraries
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
PCR and sequence analysis of ESTs. Randomly selected individual plaques from the L3 and mL3 cDNA libraries were transferred into 50 µl of SM buffer (0.1 M NaCl, 50 mM Tris-HCl [pH 7.5], 8 mM MgCl2, 0.01% gelatin). To amplify the individual cDNA inserts, PCR was carried out on 5-µl aliquots of each plaque with T3 and T7 vector primers. Thirty cycles of amplification were performed under the following conditions: 94°C for 30 s, 55°C for 30 s, and 72°C for 60 s. The PCR products were purified and then sequenced using the 5' SK vector primer and a 9600 Thermal Cycler (PE Biosystems, Foster City, Calif.). Purified sequencing reactions were resuspended in loading buffer and run on a 377 automated DNA sequencer (PE Biosystems). Sequences were edited to remove the vector sequences and poly(A) tails, and 2,935 L3 and 2,571 mL3 EST sequences were then submitted to the GenBank EST database.
Clustering and analysis of O. volvulus ESTs.
All
the sequences used in this analysis are publicly available through the
National Center for Biotechnology Information dbEST (http://www.ncbi.nlm.nih.gov/irx/dbST/dbest_query.html) or the nonredundant databases. Before clustering, clones representing rRNA or
contaminating Escherichia coli DNA were removed from the starting datasets by BLASTN comparison against the fully sequenced Brugia malayi 18S, 28S rRNA (M. L. Blaxter, personal
communication) and the E. coli genome, respectively. All
clones with BLAST probability scores of e
50 or
less to either of these datasets were eliminated from the subsequent
analysis. EST clusters were then generated using a process that
incrementally compares EST sequences against a local database using the
BLASTN algorithm (1). If an EST did not match any other
sequence in the database with a BLASTN probability score of
e
50 or less, it was then given a unique
cluster number, beginning with OVC00001, and added to the database.
When an EST matched one or more ESTs already in the database it was
assigned to that corresponding cluster. If two or more clusters had to
be merged, the cluster with the lowest number took precedence. Each
cluster, along with its member ESTs and abundance profiles were
exported into a FileMaker Pro database (Filemaker, Inc., Santa Clara,
Calif.) Consensus sequences for the clusters were generated using PHRAP (provided courtesy of P. Green with minor modifications by S. J. Jones) or AssemblyAlign (Oxford Molecular, Oxford, United Kingdom). The
major open reading frames for consensus sequences were then predicted
using MacVector (Oxford Molecular) and analyzed using PSORT
(54) (http://psort.nibb.ac.jp/) to determine if the
predicted amino acid sequence contained a potential secretory leader
(SECL+). In addition, ESTs or consensus sequences were used in
BLASTX or TBLASTX searches of Genpep (GenBank's nonredundant protein
database [http://www.ncbi.nlm.nih.gov:80/blast]),
wormpep19 (>19,000 genes predicted from the Caenorhabditis
elegans genome
[http://www.sanger.ac.uk/Projects/C_elegans /wormpep/]),
and a database constructed from clustered ESTs sequenced from the
closely related lymphatic filarial nematode B. malayi to
identify homology with other known genes. Clusters representing genes
that are possible drug targets (such as proteinases and receptors) or
otherwise interesting were identified using text-based searches of
dbEST (http://www.ncbi.nlm.nih.gov/irx/dbST /dbest_query.html).
Immunoscreening of the O. volvulus mL3 cDNA expression library using a pool of sera from PI individuals. A pool of sera from individuals living in Ecuador and Liberia who were identified and classified as putatively immune to O. volvulus infection (29, 54) was used to immunoscreen 106 PFU of the amplified O. volvulus mL3 cDNA according to standard procedures. Prior to screening the libraries, and in order to reduce redundancy, the serum pool was depleted of antibodies by affinity chromatography against recombinant O. volvulus antigens previously cloned and characterized in S. Lustigman's laboratory. Recombinant antigens which were isolated by immunoscreening of L3, L4, or adult female cDNA libraries using rabbit anti-L3 and -L4 (Ov9M, Ov-10-1, and Ov6-5) or PI sera from Liberia and Ecuador (Ov-CPI-2, Ov-GRP-1, Ov-RAL-2, Ov-API-1, Ov-ALT-1, Ov-GBP-2, Ov-FBA-1, Ov-ASP-1, Ov-CPL-1, OvB8, OvB95, and Ov103) were used for depletion as described (32). pBluescript plasmid DNA from the mL3 immunoreactive clones was isolated by the rapid in vivo excision protocol according to the manufacturer's instructions (Stratagene). Plasmid DNA was then purified using the Concert Rapid Plasmid Purification System (Life Technologies). Nucleotide sequences were obtained using an ABI 373XL sequencer (PE Biosystems). Sequence analysis was performed using the Vector NTI Suite (Informax Inc., Bethesda, Md.) software and World Wide Web interface.
Expression of recombinant proteins.
The open reading frames
of the cDNA clones isolated by immunoscreening were inserted into the
multiple-cloning site of the pProEX HT expression vector (Life
Technologies), designed for the expression of hexahistidine-tagged
fusion proteins in E. coli DH5
. Following induction with
1 mM IPTG (isopropyl-
-D-thiogalactopyranoside), bacterial cells were harvested and lysed in B-PER reagent (Pierce, Rockford, Ill.). Both soluble and insoluble E. coli
fractions were tested for the presence of corresponding recombinant
protein by Western blot analysis using the India HisProbe-HRP kit
(Pierce). Recombinant proteins were purified either under nondenaturing conditions using the Xpress System Protein Purification (Invitrogen), or by preparative sodium dodecyl sulfate-polyacrylamide gel
electrophoresis using the PrepCell (Bio-Rad, Hercules, Calif.)
according to manufacturers' instructions.
ELISA. Individual human serum samples from subjects living in the onchocerciasis endemic region of Kumba, Cameroon, were analyzed for reactivity with recombinant antigens by enzyme-linked immunosorbent assay (ELISA). Subjects who were positive for microfilariae in skin biopsies, with symptomatic or nonsymptomatic infections, and had never been previously treated for onchocerciasis were categorized as infected individuals (INF) (n = 21). Individuals who were negative for skin microfilariae, with no clinical history of infection, and who were negative in a PCR-based assay for an O. volvulus specific tandem repeat DNA in their skin biopsies (83) were classified as PI (n = 21) (74). ELISA was performed as described (36) using 50 to 100 ng of purified recombinant protein per well and a serum dilution of 1:200. The serum samples were blocked with E. coli extract (400 µg/ml; Promega, Madison, Wis.) prior to incubation with the antigen. Bound antibodies were detected by reaction with a 1:3,000 dilution of horseradish peroxidase-conjugated goat anti-human immunoglobulin G (IgG) (Zymed, San Francisco, Calif.) and 3,3',5,5'-tetramethylbenzidine substrate (Sigma, St. Louis, Mo.). Absorbance was measured at 450 nm (SpectraMax 190 ELISA Reader; Molecular Devices, Sunnyvale, Calif.). The control sera used were from healthy New York resident blood donors. Differences in the immunoglobulin levels between groups were compared using the two-tailed non-parametric Mann-Whitney U test. Results were considered statistically significant if the P value was less than 0.05.
| |
RESULTS |
|---|
|
|
|---|
Characteristics of the O. volvulus cDNA libraries. After filtering for contaminating rRNA and E. coli sequences, analysis of 2,554 ESTs from the L3 cDNA library showed that 28% were novel to the public databases, 64% had significant similarity to proteins in GenBank, and 57% had significant similarity to ESTs sequenced from the lymphatic filarial nematode B. malayi. Of the ESTs, 40% had significant similarities to proteins in wormpep19 (>19,000 proteins predicted from the C. elegans genome), and 7% had similarities only to proteins in wormpep19. Analysis of 2,081 EST sequences from the mL3 cDNA library showed that 26% were novel to public databases, 63% had significant similarity to proteins in GenBank, and 56% had significant similarity to ESTs sequenced from B. malayi. 55% of the ESTs had significant similarities to proteins in wormpep19, and 11% had similarities only to proteins in wormpep19.
Gene expression profiles in O. volvulus L3 and mL3
larvae.
Analysis of the clustered O. volvulus ESTs and
cross-comparison of the ESTs from the L3 and mL3 libraries revealed a
differential distribution of ESTs in both datasets, as summarized in
Table 1. We found genes within the
present O. volvulus database that are differentially
expressed and/or up-regulated in the L3 and mL3 stages relative to
other larval (microfilaria and L2) and adult stages. Some of these
genes encode previously characterized structural and housekeeping
proteins found in all metazoans, such as actin, 26S proteasome
subunits, and histones. Others are active components in the metabolism
of the parasite such as glyceraldehyde-3-phosphate dehydrogenase and
fructose-bisphosphate aldolase. Although these genes are not expected
to be stage specific, the high metabolic activity of the L3 and mL3 may
require their up-regulation during these stages of development relative
to the adult stages. Several up-regulated genes in L3 and/or mL3 were
previously characterized as antigens such as Ov-RAL-2,
OvL3-1, beta-galactoside-binding lectin, and onchocystatin (7, 41,
47, 56). The biological or immunological functions of these genes
in the parasite-host relationship have been the subject of much
discussion. However, their high representation in these datasets
supports the overall hypothesis that they are playing an important role
in some aspect of the biology of L3 and/or mL3, such as adaptation to
the host environment. The other L3 and/or mL3 up-regulated clusters
represent genes that have not been characterized in filariae and many
are either completely novel or only have similarity to genes predicted in the C. elegans genome (11).
|
Genes of interest identified by the EST initiative.
Not all
genes that are attractive for vaccine or drug development are stage
specific or produce abundant transcripts. If a particular gene or class
of genes is believed to be an appropriate target based on studies done
in other systems, their homologues in O. volvulus can
be identified within the EST dataset (including the approximately 2,000 clusters that have only one EST) (Table 2). The categories of genes listed below
encode proteins that are important for the development and survival of
the parasite within the host. Not surprisingly, we were also able to
identify ESTs corresponding to several immunodominant proteins that had previously been cloned from other O. volvulus cDNA
expression libraries by immunoscreening
(http://helios.bto.ed.ac.uk/mbx/fgn/OnchoNet/onchotable1.html), some of which are also being pursued for diagnostic and vaccine development purposes.
|
(i) Genes involved in the regulation of the immune response. In surveying the ESTs from the L3 and mL3 cDNA libraries, we have been able to identify several genes whose products show similarity to proteins utilized by the immune system and thus may be involved in the manipulation of host immune responses. These include two homologues of macrophage migration inhibitory factor, O. volvulus mif-1 and mif-2 (Ov-mif-1 and Ov-mif-2). The Brugia homologue of Ov-mif-1 has been shown to be secreted and have a cytokine-like activity (60), but its exact role in the manipulation of the immune response is still unknown. Galectins are beta-galactoside-binding lectins found in a variety of organisms, including nematodes. A galectin (Ov-gbp-2) that had been previously isolated by immunoscreening of the O. volvulus L3 library with PI sera (40) was identified in our EST survey and found to be up-regulated (18 ESTs and in L3 and mL3 stages only). Another galectin (Ov-gbp-1) which had been previously isolated by immunoscreening of an O. volvulus adult female cDNA library using loiasis patient sera was shown to specifically bind IgE (and not IgG) in a lactose-inhibitable manner, suggesting its role in the pathophysiology of filarial infections (41).
(ii) Proteinases. Proteolytic enzymes have been identified as drug targets and vaccine candidates in a variety of disease systems. Three different putative proteinase genes have been identified from the L3 and mL3 EST sequences. The highly expressed Ov-cpl-1 (16 ESTs in L3 only) shows high homology to cathepsin L-like enzymes, whereas the Ov-cpb-1 is similar to a large family of C. elegans cathepsin B-like enzymes. Cathepsin L-like enzymes have been isolated from a variety of nematodes, including C. elegans, D. immitis, Haemonchus contortus, T. canis, and Ancylostoma caninum. The D. immitis, Brugia pahangi, and O. volvulus cathepsins have been shown to play a vital role in molting (Guiliano et al., unpublished data). The third proteinase identified, encoded by a gene of cluster OVC00100, is similar to a large family of astacin-like metalloproteinases from C. elegans with tsp (thrombospondin and properdin)-like repeats. Metalloproteinases have been shown to be involved in molting in some nematodes. A 44-kDa zinc-metalloprotease in H. contortus was shown to be responsible for the digestion of the ring region of the L2 cuticle before molting (24). D. immitis and B. pahangi metallopeptidases were also shown to be intimately associated with molting as well as activities that might facilitate larval migration (31, 64).
(iii) Proteinase inhibitors. Specific protein inhibitors of proteinases have been isolated from filarial nematodes and were suggested to play a role in the inhibition of enzymes secreted from host immune cells (81, 82), blocking of antigen processing (W. F. Gregory, personal communication) and control of endogenous proteinases involved in parasite development (47). We identified five proteinase inhibitors in the L3 and mL3 EST datasets. Two are cystatin-like cysteine proteinase inhibitors (encoded by Ov-cpi-1 and Ov-cpi-2). The Ov-cpi-2 gene product was originally cloned as an antigen, onchocystatin, from O. volvulus (47) and has also been recently characterized in B. malayi (25) and A. viteae (26). While Ov-cpi-2 is transcribed throughout the parasite life cycle, it is clearly up-regulated in O. volvulus L3 (59 ESTs out of 70 are only in L3 [Tables 1 and 2]), where it was proposed to play a role in molting (47). The B. malayi cpi-2 is present in the ES products of larval and adult parasites, and the recombinant protein inhibits antigen processing (W. F. Gregory, personal communication), while Av17 was shown to directly inhibit T-cell proliferation (26). The serine proteinase inhibitor (Ov-spn-1) of the serpin family has a homologue in B. malayi (Bm-spn-1) that was shown to be highly expressed in L3 but not in L4 or adults and to be present in the ES products, where it is believed to interact with serum proteins (81). The second serine proteinase inhibitor (Ov-spi-1) belongs to a novel family of low-molecular-weight inhibitors originally isolated from Ascaris suum (3), where they are thought to be involved in protecting the nematodes from host trypsin and chymotrypsin activities. The Ov-spi-1 gene appears to be up-regulated in the mL3 (19 ESTs out of 22), and its function in O. volvulus is currently under investigation (D. Guiliano and S. Lustigman, unpublished data). Other members of this family have recently been identified in Anisakis simplex and A. suum (55) as well as in the C. elegans genome (11). An up-regulated aspartyl protease inhibitor (Ov-api-1) in mL3 was previously characterized as an immunodominant antigen (Ov33) in O. volvulus (77). Ov-spi-1 and Ov-api-1 genes code for part of a family of proteinase inhibitors originally characterized from Ascaris and which has not been seen outside of the phylum Nematoda (3, 51). These inhibitors could support the identification of synthetic molecules to specifically inhibit the endogenous or exogenous corresponding enzymes, and thus interfere with the function of these molecules during development in the host.
(iv) Antioxidant and detoxification enzymes. Several genes encoding antioxidant and detoxification enzymes (three superoxide dismutases [SOD], two glutathione-S-transferases [GST], and two thioredoxin peroxidases [TPX]) have already been cloned using PCR approaches and are well characterized in O. volvulus (69). All of these genes are represented in the L3 and mL3 EST datasets, of which Ov-tpx-2, Ov-sod-1, and Ov-sod-2 are abundantly expressed in both L3 and mL3 (82, 18, and 14 ESTs, respectively). These antioxidant and detoxification enzymes are believed to play a role in protecting the nematodes from host immune effector mechanisms and are being pursued as drug targets (69).
(v) Nuclear hormone receptors. Nuclear hormone receptors have been implicated in several important aspects of nematode biology, including sex determination (9), dauer formation (2), molting (44), and early development and reproductive functions (80). Human hormone receptors have been targets of rational drug design programs which aim to develop compounds that can control hormone receptor activity (52). The Macrofil Chemotherapy Project of the World Health Organization has identified nematode nuclear hormone receptor receptors as potential drug targets and is interested in developing reagents that will interfere with their function. Two nuclear hormone receptors have been identified in the L3 and mL3 EST datasets, potential steroid-thyroid-retinoic and thyrotropin receptors. Both have putative orthologues in C. elegans, which could be then used as a model system to help determine their function during development of the nematode and test possible antagonists (43).
(vi) Neurotransmitter receptors. Drugs such as avermectin and levamisole that interfere with neurotransmitter receptors are already used as nematicides, making them attractive for developing novel chemotherapeutic agents. Although not abundant, four distinct potential neurotransmitter receptors have been identified in the L3 and mL3 EST datasets (acetylcholine, ligand-gated ionic channel, GABA-glycine, and ionotropic GABA receptors). All of these have homologues or orthologues in C. elegans. Only OVC01230, which is a subunit of ionotrophic GABA receptor UNC-49, has a characterized C. elegans mutant, with an uncoordinated phenotype (4).
(vii) Developmental genes.
Single ESTs in the L3 and mL3
datasets have been identified which encode proteins whose homologues
are involved in C. elegans early development. OVC01723 is
related to C. elegans mom-5, a secreted frizzled protein
which is part of the wnt signaling pathway and controls cell
fate in the developing embryo (66). The OVC00701 gene
cluster is a homologue of C. elegans sma-2, a member of the dwarfin family of proteins, which are part of a transforming growth factor
signal transduction pathway (68). Because of the
experimental limitations in the manipulation of parasitic nematodes,
there have been very few studies investigating their developmental
biology at the molecular level. C. elegans as a model
metazoan and nematode can offer insights into nematode developmental
biology and thus new opportunities in the discovery of strategies of
interrupting the parasite life cycle.
(viii) Cyclophilins. Cyclophilins are a diverse group of proteins that were originally characterized because they were the target of the immunosuppressive drug cyclosporin A. Five distinct cyclophilins were identified in the L3 and mL3 EST datasets, all having orthologues in C. elegans. In filariae, several cyclophilins and their cyclosporin sensitivities have been described (50, 57). Three of the onchocerca cyclophilins have not been previously characterized in filariae (those in clusters OVC00488, OVC01004, and OVC01257). Cyclophilins are currently being pursued as targets for novel anthelminthics (13, 14). In nematodes, cyclophilins have also been implicated in the processing of cuticle components (57, 58) and are therefore important for the development of the parasite in the host.
Isolation of immunoreactive clones from the O. volvulus mL3 cDNA library. Eight distinct genes were isolated by immunoscreening with depleted PI sera, two of which had been previously isolated in other laboratories: the O. volvulus repetitive antigen (10) and the intermediate filament antigen (12). Following GenBank database similarity searches, the other six proteins were classified as either novel O. volvulus proteins with similarity to other known proteins (to dynein [Ov-DLC-1], calcium-binding protein [Ov-CBP-1], and guanosine 5'-monophosphate oxidoreductase [Ov-GMR-1]) or as novel O. volvulus proteins with no similarity to other known proteins, designated novel immunogenic proteins (NIP) (Ov-NIP-1, Ov-NIP-2, and Ov-NIP-3). Without the immunoscreening results, none of these antigens would have been selected for immunological studies since they all appear to be rare transcripts as depicted by their corresponding representation in the EST datasets (0 to 2 ESTs). Additionally, some are conserved and ubiquitous proteins and three of them are completely novel.
(i) Novel O. volvulus immunogenic proteins with similarity to known proteins. The Ov-dlc-1 cDNA (GenBank accession number AF153718) encodes a 9.3-kDa protein that shows extensive similarity to the cytoplasmic dynein light chain (DLC) (47). Dyneins are highly conserved proteins involved in various types of microtubule-based intracellular transport and motility and also in changing or maintaining the spatial distribution of the cytoskeletal structure (6). A comparison of Ov-DLC-1 with other DLCs shows 75% identity with Schistosoma mansoni DLC-1 (30), 73% identity with the S. mansoni DLC-2 (42), 94% identity with human DLC (17), 99% identity with a predicted C. elegans DLC (GenBank accession number Q22799), and 100% identity with B. malayi DLC (GenBank accession number AA542793). Despite the high degree of identity between the parasite and the human primary amino acid sequences (73%), the S. mansoni DLC (Sm-DLC-2, Sm10) was described as a T-cell-stimulating antigen associated with protective immunity in humans (42). Dynein and other structural housekeeping genes such as calponin, tropomyosin, and paramyosin have also been demonstrated to be of immunological importance in onchocerciasis (33, 35, 71). No EST corresponding to Ov-dlc-1 was found in the present O. volvulus EST database (9,000 ESTs as of February 2000).
The Ov-cbp-1 cDNA (GenBank accession number AF153720 [OVC02120]) encodes a 62-kDa protein with seven classical EF-hand calcium-binding domains. This protein does not show significant similarity to previously described EF-hand calcium-binding proteins present in the database and may represent a novel member of this family. Interestingly, Ov-CBP-1 shows 60% identity to a predicted C. elegans calcium-binding protein (CBP-1 [K01A2.11b]), and both of them have putative N-terminal signal peptides and are therefore probably secreted. There is one molting larval EST (SWOv3MCAM07A01SK) corresponding to this cDNA in the current EST database. An alignment of the deduced primary amino acid sequence of the Ov-gmr-1 cDNA (GenBank accession number AF153721 [OVC01489]) shows extensive identities with the two known GMP reductases from other nematodes: C. elegans (73%) and A. suum (81%), as well as the human protein (63%). One corresponding EST sequence (SWOvL3CAN62B09SK) was identified in the L3 EST dataset.(ii) Novel O. volvulus immunogenic proteins. A TBLASTX analysis revealed that three cDNA clones isolated by immunoscreening contained no homologues in the current public database. The cDNA clone designated Ov-nip-1 (GenBank accession number AF153719 [OVC00547]) encodes a highly basic (pI = 11.2) 32-kDa protein rich in serine, arginine, and lysine. The N-terminal portion of the protein is predominantly serine and arginine rich (58%) while the C-terminal region is lysine rich (38%). Two ESTs corresponding to this cDNA (SWOvL3CAN16C05SK and SWOv3MCA657SK) have been identified. This protein contains four classical (29) and six bipartite (65) nuclear localization signals. The Ov-nip-2 cDNA (GenBank accession number AF153723 [OVC00949]) encodes a 48-kDa protein with one potential N glycosylation site. The cDNA has a corresponding EST (SWOv3MCA915SK) in the mL3 EST dataset. The Ov-nip-3 cDNA (GenBank accession number AF153722 [OVC00115]) encodes a small protein (15 kDa) with a potential signal peptide. The cDNA has three corresponding EST sequences in the mL3 dataset (SWOv3MCAM07G11SK, SWOv3MCA061SK, and SWOv3MCAM11B11SK). Based on their novelty and immunogenicity, these proteins all represent a very attractive subset whose potentials as vaccinogens are currently being pursued.
Antibody responses to O. volvulus recombinant
proteins.
Serum samples from PI and INF individuals were tested
against the recombinant Ov-DLC-1, Ov-NIP-1,
Ov-NIP-2, Ov-NIP-3, and Ov-CBP-1 (Fig.
1). The mean optical density (OD) of
three normal human serum samples plus three times the standard
deviation (OD = 0.3) determined the cut-off level. Sera from 100%
of the PI and the INF individuals recognized the recombinant proteins.
The levels of recognition by both groups were high for all antigens (median ODs between 0.72 and 1.89). Only the response of the INF individuals to the Ov-CBP-1 protein (OD = 1.89) was
significantly higher than in the PI group (OD = 1.55; P = 0.03). Difficulties in expressing recombinant Ov-GMR
did not allow us to determine the immunogenicity of this protein in
both groups.
|
| |
DISCUSSION |
|---|
|
|
|---|
The search for filarial drug targets and/or vaccine candidates has so far been based largely on one of the following approaches: (i) immunoscreening of cDNA expression libraries using patient sera or monoclonal antibodies, (ii) two-dimensional Western blots using parasite protein extracts and polyspecific patient sera followed by protein sequencing and cloning, or (iii) PCR amplification of genes based on rational (hypothesis-driven) design. With the inception of the filarial genome projects and the vast amount of information contained therein, an entirely new subset of genes have been identified as possible parasite target molecules which may not have been discovered using only the above methods. The resources of the recently completed C. elegans genome (11) are being exploited as a model for analysis of filarial genes, aimed at cataloging the complete inventory of such proteins as immunogens (for vaccine development) and drug targets (for chemotherapy) as well as virulence and developmental factors (21, 78). Several important genes, like transporters, receptors, proteinases, antioxidants, and abundant and developmentally regulated transcripts, have been identified in B. malayi and T. canis using such a gene discovery approach (5, 25, 73). Unlike in B. malayi, where the complete genome and gene expression profile are being investigated, only the EST approach is being undertaken in O. volvulus using specific life cycle stages of the parasite. In the present study, we have employed a combination of two strategies to identify potential vaccine candidates and drug targets in the filarial parasite O. volvulus: analysis of 4,635 L3 and mL3 ESTs and a selective immunoscreening of the O. volvulus mL3 cDNA library using a distinct source of human sera. These two complementary approaches facilitated the identification of potentially interesting genes which can be pursued for development of vaccines and/or drug targets against onchocerciasis based on their immunogenicity, up-regulation in larval stages, and/or predicted biological features.
The EST analysis approach (Table 1) has revealed an important group of genes that are developmentally up-regulated in L3 and/or mL3, as well as proteins that are entirely novel and may be specific to O. volvulus and thus associated with infection and host-parasite interactions. Other proteins have similarity only to proteins predicted from the C. elegans genome, representing an additional group of nematode proteins that can be more easily studied using C. elegans as a model organism. In particular, with the availability of RNA interference (RNAi) technology (22) the function and importance of the C. elegans homologues for survival and/or development could be rapidly assessed. Many of these proteins from both groups have potential signal peptides and are thus presumably destined for secretion, making them another attractive subset, since ES products have been demonstrated to be valuable candidates for vaccine development in filarial infections (32). In the EST initiative, we have identified, among several others, four previously uncharacterized neurotransmitter receptors, three proteinases, two nuclear hormone receptors, and three novel cyclophilins. Compounds such as ivermectin that interrupt neurotransmission are already in use as anthelminthics, and there is a great deal of information about their effects on nematodes and their efficacy in human infections. However, very few of their targets have been cloned and characterized, and the EST sequencing approach could offer interesting starting points for drug development. Additionally, the presence of homologues of O. volvulus proteins in C. elegans would allow its use as a model organism for the development of compounds that may interfere with the function of these proteins as therapeutic targets.
The immunoscreening approach directly identified parasite immunogens that otherwise would not have been identified as potential vaccinogens using the EST approach. None of these antigens would have been selected for immunological studies, as they either are absent or have only one to three ESTs within the datasets. In addition, some of them are conserved and/or ubiquitous proteins, and three of them are completely novel. Some protective novel antigens identified by immunoscreening of L3 or adult worm cDNA libraries are also not yet represented in the EST datasets (http://helios.bto.ed.ac.uk/mbx/fgn/OnchoNet/onchotable1.html). The ELISA data indicate that the five antigens isolated from the mL3 cDNA library were strongly recognized by sera from both the PI and the INF groups (Fig. 1). As the concept of concomitant immunity has been enunciated with regard to human filarial infections (16, 74), we propose that the comparable immune responses towards the cloned antigens by the PI and INF individuals indicate that these proteins may be participating in protective responses in both groups. None of the recombinant onchocerca antigens identified so far to be protective in the mouse model were found to be uniquely recognized by the PI. The recombinant proteins corresponding to the clones isolated by the immunoscreening approach will have to be tested in the O. volvulus mouse diffusion chamber model to confirm their relevance in conferring protection against infection.
The strength of using the dual strategy of EST analysis and immunoscreening is that both approaches have effectively uncovered potential vaccine candidates and drug targets in O. volvulus. To increase the value of our findings, additional research will be required to confirm the importance of the clones identified by the EST approach. (i) Potent inhibitors of previously characterized drug targets in other systems, whose homologues have been identified in this study, can be used to screen for their effect on O. volvulus worms or an appropriate model. (ii) Plaques expressing recombinant proteins that are L3- and/or mL3-specific (based on EST analysis) can be tested with sera from protected hosts to identify those that are immunogenic and therefore more associated with protective immunity. (iii) Extracts can be used to deplete sera in order to preselect for antibodies directed against larva-specific antigens. The depleted sera can then be used on selected cDNA expression arrays to rapidly identify larva-specific genes and simultaneously assess the immunogenicity of clones of interest. Interestingly, some of the highly expressed stage-specific and/or up-regulated genes in the L3 library have already been shown to be antigenic (ALT, ASP, CPI-2) (39, 47, 70). (iv) Plaque cellular proliferation assays can also be performed using arrays of such genes designed to select those that are able to induce particular cytokine responses in PI versus INF individuals. (v) Selected genes could be subcloned into mammalian expression vectors and then used for DNA immunization in the O. volvulus mouse diffusion chamber model (45). The combination of molecular and immunological approaches has thus provided us with tools that will be used in our continuing effort to elucidate a proactive method of combating onchocerciasis.
| |
ACKNOWLEDGMENTS |
|---|
We thank Mark Blaxter, Judith Allen, and Rick Maizels for their helpful comments on the manuscript. We also thank Roselle Hoffmaster, Michelle Mondoux, Lou Ann Bierwert, and Susan Haynes for their technical assistance.
This work was financially supported in part by the grants from The Edna McConnell Clark Foundation and by grant RO1 AI 42328-02 from the National Institutes of Health. D.B.G. was funded by the United Kingdom Medical Research Counsel.
M.L.-Z., W.T., and D.B.G. contributed equally to this work.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Lindsley F. Kimball Research Institute, New York Blood Center, 310 E. 67th St., New York, NY 10021. Phone: (212) 570-3119. Fax: (212) 570-3121. E-mail: slustigm{at}nybc.org.
Editor: J. M. Mansfield
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Altschul, S. F.,
T. L. Madden,
A. A. Schaffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
25:3389-3402 |
| 2. | Antebi, A., J. G. Culotti, and E. M. Hedgecock. 1998. daf-12 regulates developmental age and the dauer alternative in Caenorhabditis elegans. Development 125:1191-1205[Abstract]. |
| 3. | Babin, D. R., R. J. Peanasky, and S. M. Goos. 1984. The isoinhibitors of chymotrypsin/elastase from Ascaris lumbricoides: the primary structure. Arch. Biochem. Biophys. 232:143-161[CrossRef][Medline]. |
| 4. |
Bamber, B. A.,
A. A. Beg,
R. E. Twyman, and E. M. Jorgensen.
1999.
The Caenorhabditis elegans unc-49 locus encodes multiple subunits of a heteromultimeric GABA receptor.
J. Neurosci.
19:5348-5359 |
| 5. | Blaxter, M. L., N. Raghavan, I. Ghosh, D. Guiliano, W. Lu, S. A. Williams, B. Slatko, and A. L. Scott. 1996. Genes expressed in Brugia malayi infective third stage larvae. Mol. Biochem. Parasitol. 77:77-93[CrossRef][Medline]. |
| 6. | Bloom, G. S. 1992. Motor proteins for cytoplasmic microtubules. Curr. Opin. Cell Biol. 4:66-73[CrossRef][Medline]. |
| 7. | Bradley, J. E., R. S. Tuan, K. J. Shepley, T. I. Tree, R. M. Maizels, R. Helm, W. F. Gregory, and T. R. Unnasch. 1993. Onchocerca volvulus: characterization of an immunodominant hypodermal antigen present in adult and larval parasites. Exp. Parasitol. 77:414-424[CrossRef][Medline]. |
| 8. | Burglin, T. R., E. Lobos, and M. L. Blaxter. 1998. Caenorhabditis elegans as a model for parasitic nematodes. Int. J. Parasitol. 28:395-411[CrossRef][Medline]. |
| 9. | Carmi, I., J. B. Kopczynski, and B. J. Meyer. 1998. The nuclear hormone receptor SEX-1 is an X-chromosome signal that determines nematode sex. Nature 396:168-173[CrossRef][Medline]. |
| 10. | Catmull, J., D. Zhang, F. Ruggiero, D. B. Copeman, and D. J. Miller. 1994. Identification and characterisation of a novel repetitive antigen from Onchocerca spp. Mol. Biochem. Parasitol. 63:49-57[CrossRef][Medline]. |
| 11. |
The C. elegans Sequencing Consortium.
1998.
Genome sequence of the nematode C. elegans: a platform for investigating biology.
Science
282:2012-2018 |
| 12. | Chandrashekar, R., K. C. Curtis, and G. J. Weil. 1995. Molecular characterization of a parasite antigen in sera from onchocerciasis patients that is immunologically cross-reactive with human keratin. J. Infect. Dis. 171:1586-1592[Medline]. |
| 13. | Chappell, L. H., and J. M. Wastling. 1992. Cyclosporin A: antiparasite drug, modulator of the host-parasite relationship and immunosuppressant. Parasitology 105:S25-S40. |
| 14. | Cully, D. F., D. K. Vassilatis, K. K. Liu, P. S. Paress, L. H. Van der Ploeg, J. M. Schaeffer, and J. P. Arena. 1994. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 371:707-711[CrossRef][Medline]. |
| 15. | Daub, J., A. Loukas, D. I. Pritchard, and M. Blaxter. 2000. A survey of genes expressed in the adults of the human hookworm, Necator americanus. Parasitology 120:171-184. |
| 16. | Day, K. P., W. F. Gregory, and R. M. Maizels. 1991. Age-specific acquisition of immunity to infective larvae in a bancroftian filariasis endemic area of Papua New Guinea. Parasite Immunol. 13:277-290[Medline]. |
| 17. | Dick, T., K. Ray, H. K. Salz, and W. Chia. 1996. Cytoplasmic dynein (ddlc1) mutations cause morphogenetic defects and apoptotic cell death in Drosophila melanogaster. Mol. Cell. Biol. 16:1966-1977[Abstract]. |
| 18. | Donelson, J. E., B. O. Duke, D. Moser, W. L. Zeng, N. E. Erondu, R. Lucius, A. Renz, M. Karam, and G. Z. Flores. 1988. Construction of Onchocerca volvulus cDNA libraries and partial characterization of the cDNA for a major antigen. Mol. Biochem. Parasitol. 31:241-250[CrossRef][Medline]. |
| 19. | Eisenbiess, W. F., H. Apfel, and T. F. Meyer. 1994. Protective immunity linked with a distinct developmental stage of a filarial parasite. J. Immunol. 152:735-742[Abstract]. |
| 20. | Elson, L. H., R. H. Guderian, E. Araujo, J. E. Bradley, A. Days, and T. B. Nutman. 1994. Immunity to onchocerciasis: identification of a putatively immune population in a hyperendemic area of Ecuador. J. Infect. Dis. 169:588-594[Medline]. |
| 21. | The Filarial Genome Project. 1999. Deep within the filarial genome: progress of the filarial genome project. Parasitol. Today 15:219-231[CrossRef][Medline]. |
| 22. | Fire, A., S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811[CrossRef][Medline]. |
| 23. | Frank, G. R., C. A. Tripp, and R. B. Grieve. 1996. Molecular cloning of a developmentally regulated protein isolated from excretory-secretory products of larval Dirofilaria immitis. Mol. Biochem. Parasitol. 75:231-240[CrossRef][Medline]. |
| 24. | Gamble, H. R., J. P. Purcell, and R. H. Fetterer. 1989. Purification of a 44 kilodalton protease which mediates the ecdysis of infective Haemonchus contortus larvae. Mol. Biochem. Parasitol. 33:49-58[CrossRef][Medline]. |
| 25. | Gregory, W. F., M. L. Blaxter, and R. M. Maizels. 1997. Differentially expressed, abundant trans-spliced cDNAs from larval Brugia malayi. Mol. Biochem. Parasitol. 87:85-95[CrossRef][Medline]. |
| 26. | Hartmann, S., B. Kyewski, B. Sonnenburg, and R. Lucius. 1997. A filarial cysteine protease inhibitor down-regulates T cell proliferation and enhances interleukin-10 production. Eur. J. Immunol. 27:2253-2260[Medline]. |
| 27. |
Hawdon, J. M.,
B. F. Jones,
D. R. Hoffman, and P. J. Hotez.
1996.
Cloning and characterization of Ancylostoma-secreted protein. A novel protein associated with the transition to parasitism by infective hookworm larvae.
J. Biol. Chem.
271:6672-6678 |
| 28. | Hawdon, J. M., S. Narasimhan, and P. J. Hotez. 1999. Ancylostoma secreted protein 2: cloning and characterization of a second member of a family of nematode secreted proteins from Ancylostoma caninum. Mol. Biochem. Parasitol. 99:149-165[CrossRef][Medline]. |
| 29. | Hicks, G. R., and N. V. Raikhel. 1995. Protein import into the nucleus: an integrated view. Annu. Rev. Cell. Dev. Biol. 11:155-188[CrossRef][Medline]. |
| 30. |
Hoffmann, K. F., and M. Strand.
1996.
Molecular identification of a Schistosoma mansoni tegumental protein with similarity to cytoplasmic dynein light chains.
J. Biol. Chem.
271:26117-26123 |
| 31. | Hong, X., J. Bouvier, M. M. Wong, G. Y. Yamagata, and J. H. McKerrow. 1993. Brugia pahangi: identification and characterization of an aminopeptidase associated with larval molting. Exp. Parasitol. 76:127-133[CrossRef][Medline]. |
| 32. | Irvine, M., E. H. Johnson, and S. Lustigman. 1997. Identification of larval-stage-specific antigens on Onchocerca volvulus uniquely recognized by putative immune sera from humans and vaccination sera from animal models. Ann. Trop. Med. Parasitol. 91:67-77[Medline]. |
| 33. | Irvine, M., T. Huima, A. M. Prince, and S. Lustigman. 1994. Identification and characterization of an Onchocerca volvulus cDNA clone encoding a highly immunogenic calponin-like protein. Mol. Biochem. Parasitol. 65:135-146[CrossRef][Medline]. |
| 34. | Jenkins, R. E., M. J. Taylor, N. Gilvary, and A. E. Bianco. 1996. Characterization of a secreted antigen of Onchocerca volvulus with host-protective potential. Parasite Immunol. 18:29-42[CrossRef][Medline]. |
| 35. |
Jenkins, R. E.,
M. J. Taylor,
N. J. Gilvary, and A. E. Bianco.
1998.
Tropomyosin implicated in host protective responses to microfilariae in onchocerciasis.
Proc. Natl. Acad. Sci. USA
95:7550-7555 |
| 36. | Johnson, E. H., S. Lustigman, P. H. Kass, M. Irvine, J. Browne, and A. M. Prince. 1995. Onchocerca volvulus: a comparative study of in vitro neutrophil killing of microfilariae and humoral responses in infected and endemic normals. Exp. Parasitol. 81:9-19[CrossRef][Medline]. |
| 37. | Johnson, E. H., M. Irvine, P. H. Kass, J. Browne, M. Abdullai, A. M. Prince, and S. Lustigman. 1994. Onchocerca volvulus: in vitro cytotoxic effects of human neutrophils and serum on third-stage larvae. Trop. Med. Parasitol. 45:331-335[Medline]. |
| 38. | Johnstone, I. L., and J. D. Barry. 1996. Temporal reiteration of a precise gene expression pattern during nematode development. EMBO J. 15:3633-3639[Medline]. |
| 39. | Joseph, G. T., T. Huima, and S. Lustigman. 1998. Characterization of an Onchocerca volvulus L3-specific larval antigen, Ov-ALT-1. Mol. Biochem. Parasitol. 96:177-183[CrossRef][Medline]. |
| 40. | Joseph, G. T., T. Huima, A. Klion, and S. Lustigman. 2000. A novel developmentally regulated galectin of Onchocerca volvulus. Mol. Biochem. Parasitol. 106:187-195[CrossRef][Medline]. |
| 41. | Klion, A. D., and J. E. Donelson. 1994. OvGalBP, a filarial antigen with homology to vertebrate galactoside-binding proteins. Mol. Biochem. Parasitol. 65:305-315[CrossRef][Medline]. |
| 42. | Kohlstadt, S., P. Couissinier-Paris, A. Bourgois, B. Bouchon, K. Piper, H. Kolbe, and A. J. Dessein. 1997. Characterization of a schistosome T cell-stimulating antigen (Sm10) associated with protective immunity in humans. Mol. Biochem. Parasitol. 84:155-165[CrossRef][Medline]. |
| 43. |
Kostrouch, Z.,
M. Kostrouchova, and J. E. Rall.
1995.
Steroid/thyroid hormone receptor genes in Caenorhabditis elegans.
Proc. Natl. Acad. Sci. USA
92:156-159 |
| 44. | Kostrouchova, M., M. Krause, Z. Kostrouch, and J. E. Rall. 1998. CHR3: a Caenorhabditis elegans orphan nuclear hormone receptor required for proper epidermal development and molting. Development 125:1617-1626[Abstract]. |
| 45. | Lange, A. M., W. Yutanawiboonchai, J. B. Lok, M. Trpis, and D. Abraham. 1993. Induction of protective immunity against larval Onchocerca volvulus in a mouse model. Am. J. Trop. Med. Hyg. 49:783-788. |
| 46. | Lucius, R., G. Textor, A. Kern, and C. Kirsten. 1991. Acanthocheilonema viteae: vaccination of jirds with irradiation-attenuated stage-3 larvae and with exported larval antigens. Exp. Parasitol. 73:184-196[CrossRef][Medline]. |
| 47. |
Lustigman, S.,
B. Brotman,
T. Huima,
A. M. Prince, and J. H. McKerrow.
1992.
Molecular cloning and characterization of onchocystatin, a cysteine proteinase inhibitor of Onchocerca volvulus.
J. Biol. Chem.
267:17339-17346 |
| 48. | Lustigman, S., B. Brotman, T. Huima, A. L. Castelhano, R. N. Singh, K. Mehta, and A. M. Prince. 1995. Transglutaminase-catalyzed reaction is important for molting of Onchocerca volvulus third-stage larvae. Antimicrob. Agents Chemother. 39:1913-1919[Abstract]. |
| 49. |
Lustigman, S.,
J. H. McKerrow,
K. Shah,
L. Jing,
H. Huima,
M. Hough, and B. Brotman.
1996.
Cloning of a cysteine proteinase required for the molting of Onchocerca volvulus third-stage larvae.
J. Biol. Chem.
271:30181-30189 |
| 50. | Ma, D., X. Hong, N. Raghavan, A. L. Scott, J. S. McCarthy, T. B. Nutman, S. A. Williams, and C. K. Carlow. 1996. A cyclosporin A-sensitive small molecular weight cyclophilin of filarial parasites. Mol. Biochem. Parasitol. 79:235-241[CrossRef][Medline]. |
| 51. | Martzen, M. R., B. A. McMullen, N. E. Smith, K. Fujikawa, and R. J. Peanasky. 1990. Primary structure of the major pepsin inhibitor from the intestinal parasitic nematode Ascaris suum. Biochemistry 29:7366-7372[CrossRef][Medline]. |
| 52. | McDonnell, D. P., E. Vegeto, and M. A. Gleeson. 1993. Nuclear hormone receptors as targets for new drug discovery. Bio/Technology (New York) 11:1256-1261[Medline]. |
| 53. |
Moyle, M.,
D. L. Foster,
D. E. McGrath,
S. M. Brown,
Y. Laroche,
J. De Meutter,
P. Stanssens,
C. A. Bogowitz,
V. A. Fried,
J. A. Ely,
H. R. Soule, and G. P. Vlasuk.
1994.
A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18.
J. Biol. Chem.
269:10008-10015 |
| 54. | Nakai, K., and P. Horton. 1999. PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem. Sci. 24:34-36[CrossRef][Medline]. |
| 55. | Nguyen, T. T., M. A. Qasim, S. Morris, C. C. Lu, D. Hill, M. Laskowski, Jr., and J. A. Sakanari. 1999. Expression and characterization of elastase inhibitors from the ascarid nematodes Anisakis simplex and Ascaris suum. Mol. Biochem. Parasitol. 102:79-89[CrossRef][Medline]. |
| 56. | Oberlander, U., R. Adam, K. Berg, F. Seeber, and R. Lucius. 1995. Molecular cloning and characterization of the filarial LIM domain proteins AvL3-1 and OvL3-1. Exp. Parasitol. 81:592-599[CrossRef][Medline]. |
| 57. | Page, A. P., D. Landry, G. G. Wilson, and C. K. Carlow. 1995. Molecular characterization of a cyclosporin A-insensitive cyclophilin from the parasitic nematode Brugia malayi. Biochemistry 34:11545-11550[CrossRef][Medline]. |
| 58. | Page, A. P., and A. D. Winter. 1998. A divergent multi-domain cyclophilin is highly conserved between parasitic and free-living nematode species and is important in larval muscle development. Mol. Biochem. Parasitol. 95:215-227[CrossRef][Medline]. |
| 59. | Page, A. P. 1999. A highly conserved nematode protein folding operon in Caenorhabditis elegans and Caenorhabditis briggsae. Gene 230:267-275[CrossRef][Medline]. |
| 60. |
Pastrana, D. V.,
N. Raghavan,
P. FitzGerald,
S. W. Eisinger,
C. Metz,
R. Bucala,
R. P. Schleimer,
C. Bickel, and A. L. Scott.
1998.
Filarial nematode parasites secrete a homologue of the human cytokine macrophage migration inhibitory factor.
Infect. Immun.
66:5955-5963 |
| 61. | Pogonka, T., U. Oberlander, T. Marti, and R. Lucius. 1999. Acanthocheilonema viteae: characterization of a molt-associated excretory/secretory 18-kDa protein. Exp. Parasitol. 93:73-81[CrossRef][Medline]. |
| 62. | Prince, A. M., B. Brotman, E. H. Johnson, A. Smith, D. Pascual, and S. Lustigman. 1992. Onchocerca volvulus: immunization of chimpanzees with X-irradiated third-stage (L3) larvae. Exp. Parasitol. 74:239-250[CrossRef][Medline]. |
| 63. | Richards, F. O., E. Miri, S. Meredith, R. Guderian, M. Sauerbrey, H. Remme, R. Packard, and J. M. Ndiaye. 1998. Onchocerciasis. Bull. W. H. O. 76(Suppl. 2):147-149. |
| 64. | Richer, J. K., J. A. Sakanari, G. R. Frank, and R. B. Grieve. 1992. Dirofilaria immitis: proteases produced by third- and fourth-stage larvae. Exp. Parasitol. 75:213-222[CrossRef][Medline]. |
| 65. | Robbins, J., S. M. Dilworth, R. A. Laskey, and C. Dingwall. 1991. Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence. Cell 64:615-623[CrossRef][Medline]. |
| 66. | Rocheleau, C. E., W. D. Downs, R. Lin, C. Wittmann, Y. Bei, Y. H. Cha, M. Ali, J. R. Priess, and C. C. Mello. 1997. Wnt signaling and an APC-related gene specify endoderm in early C. elegans embryos. Cell 90:707-716[CrossRef][Medline]. |
| 67. | Sangster, N. 1996. Pharmacology of anthelmintic resistance. Parasitology 113:S201-S216. |
| 68. |
Savage, C.,
P. Das,
A. L. Finelli,
S. R. Townsend,
C. Y. Sun,
S. E. Baird, and R. W. Padgett.
1996.
Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor beta pathway components.
Proc. Natl. Acad. Sci. USA
93:790-794 |
| 69. | Selkirk, M. E., V. P. Smith, G. R. Thomas, and K. Gounaris. 1998. Resistance of filarial nematode parasites to oxidative stress. Int. J. Parasitol. 28:1315-1332[CrossRef][Medline]. |
| 70. | Taylor, M. J., N. Abdul-Wahab, R. J. Jenkins, and A. E. Bianco. 1995. Onchocerca volvulus larval antigen, OvB20, induces partial protection in a rodent model of onchocerciasis. Infect. Immun. 63:4417-4422[Abstract]. |
| 71. | Taylor, M. J., R. J. Jenkins, and A. E. Bianco. 1996. Protective immunity induced by vaccination with Onchocerca volvulus tropomyosin in rodents. Parasite Immunol. 18:219-225[CrossRef][Medline]. |
| 72. | Taylor, M. J., R. P. Van Es, K. Shay, S. G. Folkard, S. Townson, and A. E. Bianco. 1994. Protective immunity against Onchocerca volvulus and Onchocerca lienalis infective larvae in mice. Trop. Med. Parasitol. 45:17-23[Medline]. |
| 73. |
Tetteh, K. K.,
A. Loukas,
C. Tripp, and R. M. Maizels.
1999.
Identification of abundantly expressed novel and conserved genes from the infective larval stage of Toxocara canis by an expressed sequence tag strategy.
Infect. Immun.
67:4771-4779 |
| 74. |
Turaga, P. S. D.,
T. J. Tierney,
K. E. Bennett,
M. C. McCarthy,
S. C. Simonek,
P. A. Enyong,
D. W. Moukatte, and S. Lustigman.
2000.
Immunity to onchocerciasis: cells from putatively immune individuals produce enhanced levels of interleukin-5, gamma interferon, and granulocyte-macrophage colony-stimulating factor in response to Onchocerca volvulus larval and male worm antigens.
Infect. Immun.
68:1905-1911 |
| 75. | Wang, C. C. 1984. Parasite enzymes as potential targets for antiparasitic chemotherapy. J. Med. Chem. 27:1-9[CrossRef][Medline]. |
| 76. | Ward, D. J., T. B. Nutman, G. Zea-Flores, C. Portocarrero, A. Lujan, and E. A. Ottesen. 1988. Onchocerciasis and immunity in humans: enhanced T cell responsiveness to parasite antigen in putatively immune individuals. J. Infect. Dis. 57:536-543. |
| 77. | Willenbucher, J., W. Hofle, and R. Lucius. 1993. The filarial antigens Av33/Ov33-3 show striking similarities to the major pepsin inhibitor from Ascaris suum. Mol. Biochem. Parasitol. 57:349-351[CrossRef][Medline]. |
| 78. | Williams, S. A., and D. A. Johnston. 1999. Helminth genome analysis: the current status of the filarial and schistosome genome projects. Filarial Genome Project. Schistosome Genome Project. Parasitology 118:S19-S38. |
| 79. | World Health Organization. 1995. WHO Expert Committee on Onchocerciasis Control. Onchocerciasis and its control. WHO technical report series 852. World Health Organization, Geneva, Switzerland. |
| 80. | Yates, R. A., R. S. Tuan, K. J. Shepley, and T. R. Unnasch. 1995. Characterization of genes encoding members of the nuclear hormone receptor superfamily from Onchocerca volvulus. Mol. Biochem. Parasitol. 70:19-31[CrossRef][Medline]. |
| 81. | Yenbutr, P., and A. L. Scott. 1995. Molecular cloning of a serine proteinase inhibitor from Brugia malayi. Infect. Immun. 63:1745-1753[Abstract]. |
| 82. |
Zang, X.,
M. Yazdanbakhsh,
H. Jiang,
M. R. Kanost, and R. M. Maizels.
1999.
A novel serpin expressed by blood-borne microfilariae of the parasitic nematode Brugia malayi inhibits human neutrophil serine proteinases.
Blood
94:1418-1428 |
| 83. | Zimmerman, P. A., R. H. Guderian, E. Aruajo, L. Elson, P. Phadke, J. Kubofcik, and T. B. Nutman. 1994. Polymerase chain reaction-based diagnosis of Onchocerca volvulus infection: improved detection of patients with onchocerciasis. J. Infect. Dis. 169:686-689[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»